Push­ing ahead with can­cer drug re­search, Pelo­ton brings its lat­est round to $75M

Dal­las-based Pelo­ton Ther­a­peu­tics has bagged an ex­tra $22.2 mil­lion for its Se­ries D round, bring­ing the to­tal to $74.6 mil­lion.

Much of that mon­ey …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.